Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system

Journal of Clinical Virology

Volumn 31, Issue SUPPL. 1, 2004, Pages 7-15

  Ziermann, Rainer ^a   Celis, Linda ^b   Derdelinckx, Inge ^c   Lambert, Christine ^d   Veeck, Jürgen ^e   Rizzo, Maria Gabriella ^f   Vanderborght, Bart ^g   Zissis, Georges ^h   Clumeck, Nathan ^h   Fransen, Katrien ⁱ   Vaira, Dolores ^j   Hendricks, David ^a   Laethem, Kristel Van ^c   Vandamme, Anne Mieke ^c   Schmit, Jean Claude ^d   Knechten, Heribert ^e   Luca, Andrea De ^f   Louwagie, Joost ^b   Segers, Pascale ^b   Boeck, Kristel De ^b   Pottel, Hans ^b   Brauwer, Annelies De ^b   Hulstaert, Frank ^b   more..

^a BAYER CORPORATION   (United States)

^b INNOGENETICS   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d Retrovirology Laboratory Luxembourg   (Luxembourg)

^e Blondelstrasse 9   (Germany)

^f UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^g Hosp Univ Clementino Frago Filho   (Brazil)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^j UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

Antiretroviral drug resistance; HIV 1; Interpretation algorithm; Line probe assay

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TIRACIZINE; ZALCITABINE; ZIDOVUDINE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; VIRUS LOAD;

EID: 9644289437     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.09.014     Document Type: Article

References (19)

1. J.D. Baxter, D.L. Mayers, and D.N. Wentworth A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS AIDS 14 2000 F83 F93
2. C. Brites, F. Bahia, and M. Gilbert Evaluation of viral resistance to reverse transcriptase inhibitors (RTI) in HIV-1-infected patients before and after 6 months of single or double antiretroviral therapy Braz J Infect Dis 5 2001 177 182
3. ® HIV-1 RT Resistance Assay (LiPA) Proceedings of the 6th International Congress on Drug Therapy in HIV Infection Glasgow, UK, 17-21 November 2002 [Abstract]
4. P. Clevenbergh, J. Durant, and P. Halfon Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up Antivir Ther 5 2000 65 70
5. C. Cohen, S. Hunt, and M. Sension A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy AIDS 16 2002 579 588
6. A. De Luca, A. Cingolani, and S. Di Giambenedetto Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance J Infect Dis 187 2003 1934 1943
7. A. De Luca, A. Cingolani, and M.P. Trotta Prediction of virological and immunological outcomes by different interpretation systems for genotypic resistance in a cohort of highly active antiretroviral therapy-failed patients Antivir Ther 6 Suppl 1 2001 70
8. K. De Smet, L. Celis, and J.C. Schmit Identification of key mutations in the HIV-1 protease using the INNO-LiPA HIV protease assay Proceedings of the 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance Frankfurt, Germany, 25-27 February 2000 [Abstract 50]
9. J. Durant, P. Clevenbergh, and P. Halfon Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial Lancet 353 1999 2195 2199
10. M.S. Hirsch, F. Brun-Vezinet, and B. Clotet Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin Infect Dis 37 2003 113 128
11. S.J. Little, S. Holte, and J.P. Routy Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 347 2002 385 392
12. R.F. Schinazi, B.A. Larder, and J.W. Mellors Mutations in retroviral genes associated with drug resistance: 2001 update Int Antivir News 8 2000 65 91
13. M. Setti, B. Bruzzone, and F. Ansaldi Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART J Med Virol 64 2001 199 206
14. A. Tanuri, E. Caridea, and M.C. Dantas Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART J Clin Virol 25 2002 39 46
15. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20.
16. C. Tural, L. Ruiz, and C. Holtzer Clinical utility of HIV-1 genotyping and expert advice: the Havana trial AIDS 16 2002 209 218
17. K. Van Laethem, A. De Luca, A. Antinori, C.F. Perno, and A.M. Vandamme A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients Antivir Ther 7 2002 123 129
18. K. Van Vaerenbergh, K. Van Laethem, and E. Van Wijngaerden Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy AIDS Res Hum Retroviruses 16 2000 529 537
19. A.M. Vandamme, F. Houyez, and D. Banhegyi Laboratory guidelines for the practical use of HIV resistance tests in patient follow-up Antivir Ther 6 2001 21 39